Peptides - Compound guides
Tesamorelin
Tesamorelin is a GHRH analogue and a specialist prescription-only medicine, licensed in some countries for one narrow patient group and not as a body-composition product. This page explains the pharmacology; it is not a recommendation to obtain or use it.
Tesamorelin is a synthetic analogue of growth hormone releasing hormone, or GHRH - the natural hypothalamic peptide that tells the pituitary gland to release growth hormone. Natural GHRH is broken down in the bloodstream within minutes, which makes it impractical as a medicine. Tesamorelin is a modified version of the same 44-amino-acid sequence, carrying a chemical group added at one end that slows enzymatic breakdown and gives the molecule a longer working life in the body.
It was developed as a pharmaceutical product rather than emerging from the research-chemical world, and it went through the full clinical development pathway. It holds a licence in some jurisdictions - in the United States it is approved under the brand name Egrifta - for one specific, narrowly defined patient group: people with HIV who have developed a particular pattern of abdominal fat accumulation associated with their condition and its treatment. That single licensed indication is the entire scope of its regulatory approval. Understanding this compound properly means understanding how specific that approval is, because tesamorelin is frequently discussed online in a much broader way than any regulator has sanctioned.
How it is thought to work
Growth hormone release is governed by a feedback loop between the hypothalamus and the pituitary. The hypothalamus produces GHRH, which stimulates release, and somatostatin, which suppresses it. The pituitary responds by releasing growth hormone in pulses, and growth hormone in turn drives production of insulin-like growth factor 1, mostly in the liver. IGF-1 then feeds back on the system to damp further release.
Tesamorelin acts at the GHRH receptor on the pituitary. Because it works through the body's own release machinery rather than replacing growth hormone directly, the pulsatile pattern of secretion and the natural feedback brakes remain in place - the pituitary is being prompted rather than bypassed. This is the pharmacological argument that distinguishes GHRH analogues from administered growth hormone itself. It is an argument about the shape of the hormonal signal, not a claim that the approach is free of consequences.
What the research actually shows
Tesamorelin sits high on the evidence ladder relative to almost everything else discussed on this site. It was tested in randomised, placebo-controlled phase 3 trials, published in peer-reviewed journals, with pre-specified endpoints and imaging-based measurement. The trials recruited adults with HIV-associated lipodystrophy and measured visceral adipose tissue by CT scanning. Across those trials, the groups receiving tesamorelin showed reductions in measured visceral adipose tissue compared with placebo groups, and the trials also reported changes in IGF-1 levels consistent with the drug's proposed mechanism. Regulators reviewed that data package and granted a licence on the strength of it.
Two things about that evidence matter enormously and are routinely lost in online discussion. First, the studied population was people with a specific, disease-associated pattern of fat distribution - not healthy adults seeking a change in body composition. Findings in a patient population with a defined pathology do not automatically describe what happens in people without that pathology, and no regulator has accepted that extrapolation. Second, the licence is written narrowly for that indication precisely because that is what was demonstrated. A trial result in one population is evidence about that population.
The trials also documented adverse effects and metabolic changes, including effects related to glucose handling, which is why the product carries prescribing information and is dispensed under medical supervision rather than sold freely.
Where the evidence stops
- The controlled trial evidence concerns adults with HIV-associated lipodystrophy. There is no comparable body of evidence in healthy adults.
- Long-term safety beyond the trial durations, particularly with continuous use over years, is not well characterised.
- Any pharmacological approach that raises IGF-1 raises theoretical questions about cell growth that long-term human data has not fully resolved.
- Effects observed in the trials were reported to diminish after the drug was stopped, which tells you the studied changes were maintained by ongoing treatment rather than being permanent.
- The popular framing of tesamorelin as a general fat-loss or anti-ageing compound goes well beyond what was studied and well beyond what any licence covers.
Legal and regulatory status
Tesamorelin is an approved medicine in some jurisdictions, but only for its narrow licensed indication, and it is a specialist prescription-only product. It is not licensed anywhere as a general body-composition or physique product. In the UK, supplying a prescription-only medicine outside the prescription route is unlawful, and material obtained through non-prescription channels is by definition an unregulated product with no medicines-grade assurance of identity, purity, sterility or content - regardless of what the label claims. The gap between a pharmaceutical product made to licensed standards and a vial bought online is not a small one.
GHRH analogues, including tesamorelin, appear on the World Anti-Doping Agency prohibited list. Any athlete in a tested sport should treat that as decisive.
This lesson is educational content only and is not medical advice. Tesamorelin is a prescription-only medicine with a narrow licensed indication and is not approved as a general body-composition product. Nothing here is a recommendation to obtain or use it. Any decision about a prescription medicine belongs with a qualified healthcare professional who knows your medical history.
Growth-hormone secretagogues
Start with the overview: Growth-hormone secretagogues, explained
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
